Star Metro - Zomedica Launches Groundbreaking Equine Asthma Clinical Registry Featuring PulseVet(R) Shock Wave Therapy

ANN ARBOR, MI / ACCESS Newswire / May 13, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced the launch of the Equine Asthma Clinical Registry. This pioneering program leverages PulseVet® shock wave therapy to offer a non-invasive, drug-free treatment alternative for horses suffering from asthma.

Equine asthma is a common yet often underdiagnosed condition, affecting an estimated 15% of horses over the age of seven. The chronic respiratory disease can significantly impact performance, comfort, and quality of life, especially in athletic and aging horses. Zomedica's Equine Asthma Clinical Registry aims to uncover better treatment strategies through real-world clinical evidence using the PulseVet system.

Recent clinical studies have demonstrated that electrohydraulic extracorporeal shock wave therapy (ESWT) using the PulseVet device can significantly improve clinical signs in horses diagnosed with respiratory conditions. To date, 58 horses have completed treatment for respiratory conditions, with no reported adverse events.

Dr. Beau Whitaker, DVM, of Brazos Valley Equine Hospital, commented, "We've observed measurable reductions in respiratory effort, cough frequency, and overall clinical signs following ESWT treatment. It's a promising adjunct therapy for managing equine asthma."

Veterinary clinics can enroll up to 20 horses, contributing to vital research while receiving product credits. Participants are required to complete three scheduled visits per horse over a 4-6 week period, with assessments conducted at each visit.

"The launch of this clinical registry marks an important milestone in our commitment to advancing patient care. By systematically collecting real-world data for the treatment of equine asthma, we aim to generate critical insights that will inform clinical practice, guide future research, and ultimately improve outcomes for patients. This initiative reflects our ongoing dedication to evidence-based innovation and collaboration," said Ashley Wood PhD, Zomedica's Vice President of Research and Development.

Courtney Calnan, Senior Product Manager at Zomedica, added: "What makes this registry so exciting is that it bridges cutting-edge science with everyday clinical application. We're providing veterinarians with tools and data that empower them to deliver better outcomes for their patients-without relying solely on medications. It's a true step forward in equine respiratory care."

This initiative not only offers a novel treatment avenue for equine asthma but also reinforces Zomedica's commitment to advancing animal healthcare through innovative, evidence-based solutions.

For more information or to enroll in the Equine Asthma Clinical Registry, please visit: https://pulsevet.zomedica.com/shock-wave-therapy/equine-asthma-clinical-registry/

About Zomedica

Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet^® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi^® Loop line of therapeutic devices and the TRUFORMA^® diagnostic platform, the TRUVIEW^® digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 8% in 2024 to $27 million and maintains a strong balance sheet with approximately $71 million in liquidity as of December 31, 2024. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit www.zomedica.com.

Follow Zomedica

• Email Alerts: http://investors.zomedica.com

• LinkedIn: https://www.linkedin.com/company/zomedica

• Facebook: https://m.facebook.com/zomedica

• X (formerly Twitter): https://twitter.com/zomedica

• Instagram: https://www.instagram.com/zomedica_inc

Cautionary Note Regarding Forward-Looking Statements

Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes;; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact:

Zomedica Investor Relations
[email protected]
1-734-369-2555

SOURCE: Zomedica Corp.

View the original press release on ACCESS Newswire

A.Bergeron--SMC